Glucagon‐like peptide‐1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta‐analysis

AIMS: Since 2005, several glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have been approved to treat people with type 2 diabetes. These agents are considered for use at the same point in the treatment paradigm as basal insulins. A comprehensive comparison of these drug classes, therefore, can...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Sonal, Wright, Eugene E., Kwan, Anita Y. M., Thompson, Juliette C., Syed, Iqra A., Korol, Ellen E., Waser, Nathalie A., Yu, Maria B., Juneja, Rattan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299485/
https://www.ncbi.nlm.nih.gov/pubmed/27717130
http://dx.doi.org/10.1111/dom.12805

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5299485/
https://www.ncbi.nlm.nih.gov/pubmed/27717130
http://dx.doi.org/10.1111/dom.12805

Ejemplares similares